Shukra Pharmaceuticals Allots 11.73 Lakh Equity Shares on Warrant Conversion

Shukra Pharmaceuticals Limited announced the allotment of 11,73,000 fully paid-up equity shares of Re.1/- each upon the conversion of warrants into equity shares on a preferential basis. The allotment was made to Navkar Surgical Gujarat Limited, a promoter and warrant holder, on September 02, 2026.

The conversion was exercised by the warrant holders upon payment of the remaining exercise price of ₹26.67/- per share warrant, which represents 75% of the total warrant exercise price of ₹35.56/- per warrant. The total amount received for this conversion aggregated to ₹3,12,83,910/- (Rupees Three Crore Twelve Lakh Eighty-Three Thousand Nine Hundred Ten Only).

Consequent to this allotment, the company's paid-up equity capital has increased from ₹43,96,14,440/- (comprising 43,96,14,440 equity shares of Re.1/- each) to ₹44,07,87,440/- (comprising 44,07,87,440 equity shares of Re.1/- each). The newly allotted equity shares will rank pari passu with the existing equity shares of the company in all respects.

The company also provided an update on its outstanding warrants. As of September 02, 2026, a total of 17,35,000 warrants remain outstanding for conversion. Holders of these warrants are entitled to convert them into an equal number of equity shares by paying the remaining 75% of the exercise price within 18 months from the original warrant allotment date of January 28, 2026.

The Board Meeting where this allotment was approved commenced at 06:00 p.m. and concluded at 06:30 p.m. on September 02, 2026.